Editorial: Drug Repurposing

Frontiers in Medicine

article

Pan Pantziarka¹  Nicolas André⁴ 

[1] Anticancer Fund;The George Pantziarka TP53 Trust;Metronomics Global Health Initiative;Department of Pediatric Hematology-Oncology, La Timone Hospital;Centre de Recherche en Cancérologie de Marseille (CRCM, Marseille Cancer Research Centre), Aix-Marseille University UM105

关键词: drug repurposing;    oncology;    clinical cancer research;    drug development;    drug repositioning;   

DOI  :  10.3389/fmed.2019.00154

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Drug repurposing, also known as drug repositioning or reprofiling, seeks new medical treatments from among existing medications rather than through the development of de novo medicines. Although interest in drug repurposing has increased in recent years, it is part and parcel of normal commercial drug development, particularly in the field of oncology (1). The standard business model is to gain a license for a new drug in a particular cancer indication and then to seek to extend this to new cancers or settings (i.e., from second line to first line treatment). However, there are particular challenges associated with repurposing off-patent or generic drugs (2). These challenges are as much to do with economic incentives and social policy as they are scientific or medical. Repurposing then, as a specific topic, encompasses both scientific and socio-political issues, as reflected in the range of papers in this Research Topic.

【 授权许可】

CC BY